Metoprolol

證據等級: L5

預測適應症: 10 個

Metoprolol: From Hypertension/Angina to Malignant Renovascular Hypertension

One-Sentence Summary

Metoprolol is a selective beta-1 adrenergic blocker generally used to manage hypertension, angina and related cardiovascular conditions. The TxGNN model’s top-ranked prediction is that it may be effective for Malignant Renovascular Hypertension, but this direction is currently supported by 0 clinical trials and only 2 tangentially related publications (neither of which studies metoprolol directly in this condition).

Quick Overview

Item	Content
Original Indication	Not documented in the evidence pack (data gap — original indication text and TFDA label not yet retrieved)
Predicted New Indication	Malignant Renovascular Hypertension
TxGNN Prediction Score	99.91%
Evidence Level	L4
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacology, metoprolol is a cardioselective beta-1 adrenergic receptor antagonist. Beta-1 blockade reduces renin release, heart rate, and cardiac output — mechanisms that are theoretically applicable to controlling severe/malignant forms of hypertension, including malignant renovascular hypertension, which is driven substantially by renin-angiotensin system activation.

However, the theoretical mechanistic link is not currently backed by direct evidence. Malignant renovascular hypertension is a renin-driven, often surgically- or ACE-inhibitor/ARB-managed condition, and beta-blockers are typically adjunctive rather than first-line in this specific presentation. The TxGNN score is high, but this reflects a knowledge-graph relationship prediction rather than confirmed clinical benefit.

The two retrieved publications are only topically adjacent — one is a case report on hypertensive optic neuropathy from Takayasu’s arteritis-related renal artery stenosis, and the other evaluates a diagnostic biomarker (chromogranin A) for pheochromocytoma. Neither studies metoprolol’s efficacy or safety in this indication, so the mechanistic rationale should be regarded as plausible but essentially unproven.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15231398	2004	Case report	Survey of Ophthalmology	Case of hypertensive optic neuropathy from renal artery stenosis (Takayasu’s arteritis); does not evaluate metoprolol treatment
1988765	1991	Diagnostic study	Medicine	Evaluates chromogranin A vs. plasma catecholamines for diagnosing pheochromocytoma in hypertension work-up; not a metoprolol efficacy study

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, but there are no clinical trials and no literature directly evaluating metoprolol in malignant renovascular hypertension — the two retrieved papers are only topically related. Combined with the outstanding blocking data gap on TFDA warnings/contraindications, there is insufficient evidence to progress this candidate.

To proceed, the following is needed:

TFDA product label (warnings, contraindications) — currently a blocking data gap
Confirmed mechanism of action data from DrugBank
Original indication/regulatory history for metoprolol in this market
Dedicated clinical or preclinical studies of metoprolol specifically in malignant renovascular hypertension

Note: A lower-ranked candidate in this evidence pack, chronic pulmonary heart disease (rank 9, score 99.05%), has substantially stronger support — 15 clinical trials (including several Phase 4 RCTs with n>1,700) and 20 publications — with a scoring of L2/Proceed with Guardrails. This may warrant a separate, dedicated evaluation report.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.